Rodney Young
Director of Finance/CFO presso RAPT THERAPEUTICS, INC.
Patrimonio netto: 86 420 $ in data 29/02/2024
Profilo
Rodney K.
B.
Young holds the position of Chief Financial Officer & Secretary of Rapt Therapeutics, Inc.
In his past career Mr. Young was Chief Financial Officer for Cellerant Therapeutics, Inc., Chief Financial Officer of Extropy Pharmaceuticals, Inc., Chief Financial Officer, VP & Head-IR at StemCells, Inc. and Chief Financial Officer of Aimmune Therapeutics, Inc.
He received an undergraduate degree from The University of Chicago and an MBA from The University of Chicago Booth School of Business.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
RAPT THERAPEUTICS, INC.
0.03% | 31/01/2024 | 10 084 ( 0.03% ) | 86 420 $ | 29/02/2024 |
Posizioni attive di Rodney Young
Società | Posizione | Inizio |
---|---|---|
RAPT THERAPEUTICS, INC. | Director of Finance/CFO | 02/12/2019 |
Precedenti posizioni note di Rodney Young
Società | Posizione | Fine |
---|---|---|
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Director of Finance/CFO | 01/11/2019 |
AIMMUNE THERAPEUTICS, INC. | Director of Finance/CFO | 01/02/2015 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Director of Finance/CFO | 01/12/2013 |
Extropy Pharmaceuticals, Inc. | Director of Finance/CFO | 01/01/2005 |
Formazione di Rodney Young
The University of Chicago | Undergraduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
RAPT THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Extropy Pharmaceuticals, Inc. | |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |